EGF and central nervous system cancer: For instance, thalidomide is being tested in glioma and it has been shown to inhibit EGF-induced phosphorylation of extracellular signal regulated kinase (ERK), as well as EGF-induced Ras activation by preventing transition to GTP-bound active Ras (86).